Phase II study of Temodal in the treatment of patients with advanced nasopharyngeal carcinoma.
OBJECTIVE
A single-institution phase II trial of Temodal (temozolomide, SCH52365) in Chinese patients with advance nasopharyngeal carcinoma was undertaken to determine the efficacy and safety of the drug in this population.


METHODS
A total of 14 patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma were entered into the study. One patient was unevaluable. Temodal was given at doses of 150 or 200 mg/m2 daily on days 1-5 every 28 days.


RESULTS
In all, 30 cycles of Temodal were given with no significant toxicity. All 13 (100%) evaluable patients had progressive disease after 2 (84.6%) or 4 (15.4%) courses.


CONCLUSIONS
Temodal given on this schedule has no activity in advanced nasopharyngeal carcinoma.
Chan
A T
AT
Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, China. anthonytcchan@cuhk.edu.hk
Leung
T W
TW
Kwan
W H
WH
Mok
T S
TS
Yeo
W
W
Lai
M
M
Johnson
P J
PJ
D000328:Adult; D000368:Aged; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy*; D003606:Dacarbazine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000188:drug therapy*; D000077204:Temozolomide; D016896:Treatment Outcome
D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide